butyric acid has been researched along with Liver Neoplasms in 40 studies
Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.
butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.
butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is first study to unravel the association of butyrate producing bacteria with HCC patients and the significance of bacterial metabolite butyrate as anti-tumour in sorafenib resistant hepatocellular carcinoma." | 8.31 | Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma. ( Chakraborti, A; Dhiman, RK; Kanthaje, S; Kaur, R; Kumar, M, 2023) |
| " Recently, berberine (BBR) has been characterized as a modulator of PPARs; however, the matter of whether PPARs are involved in the inhibitory effect of BBR on hepatocellular carcinoma (HCC) is not well understood." | 8.31 | Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma. ( Shaw, PC; Shou, JW, 2023) |
| " Thus, the objective of this study was to kinetically evaluate the antiangiogenic activity of tributyrin (TB), a butyric acid prodrug, in the promotion stage of hepatocarcinogenesis." | 7.91 | Antiangiogenic effects of the chemopreventive agent tributyrin, a butyric acid prodrug, during the promotion phase of hepatocarcinogenesis. ( Andrade, FO; Farsky, SHP; Fernandes, LHG; Furtado, KS; Hebeda, CB; Heidor, R; Horst, MA; Miranda, MLP; Moreno, FS; Sandri, S; Yamamoto, RC, 2019) |
| " In this study, we evaluated the combination of 1'-acetoxychavicol acetate (ACA), obtained from Alpinia galangal, and sodium butyrate, a major short chain fatty acid, on the growth of HepG2 human hepatocellular carcinoma cells and found that treatment had a synergistic inhibitory effect." | 7.80 | The synergistic effect of 1'-acetoxychavicol acetate and sodium butyrate on the death of human hepatocellular carcinoma cells. ( Azuma, H; Kato, R; Kojima-Yuasa, A; Matsui-Yuasa, I, 2014) |
| "This is first study to unravel the association of butyrate producing bacteria with HCC patients and the significance of bacterial metabolite butyrate as anti-tumour in sorafenib resistant hepatocellular carcinoma." | 4.31 | Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma. ( Chakraborti, A; Dhiman, RK; Kanthaje, S; Kaur, R; Kumar, M, 2023) |
| " Recently, berberine (BBR) has been characterized as a modulator of PPARs; however, the matter of whether PPARs are involved in the inhibitory effect of BBR on hepatocellular carcinoma (HCC) is not well understood." | 4.31 | Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma. ( Shaw, PC; Shou, JW, 2023) |
| "Butyric acid (BA) has been reported to induce anticancer effects on hepatocellular carcinoma (HCC) cells both in vitro and in vivo." | 3.91 | Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells. ( Armenia, E; Barbarisi, A; Barbarisi, M; Caraglia, M; Giudice, A; Masarone, M; Persico, M; Quagliariello, V, 2019) |
| " Thus, the objective of this study was to kinetically evaluate the antiangiogenic activity of tributyrin (TB), a butyric acid prodrug, in the promotion stage of hepatocarcinogenesis." | 3.91 | Antiangiogenic effects of the chemopreventive agent tributyrin, a butyric acid prodrug, during the promotion phase of hepatocarcinogenesis. ( Andrade, FO; Farsky, SHP; Fernandes, LHG; Furtado, KS; Hebeda, CB; Heidor, R; Horst, MA; Miranda, MLP; Moreno, FS; Sandri, S; Yamamoto, RC, 2019) |
| " In this study, we evaluated the combination of 1'-acetoxychavicol acetate (ACA), obtained from Alpinia galangal, and sodium butyrate, a major short chain fatty acid, on the growth of HepG2 human hepatocellular carcinoma cells and found that treatment had a synergistic inhibitory effect." | 3.80 | The synergistic effect of 1'-acetoxychavicol acetate and sodium butyrate on the death of human hepatocellular carcinoma cells. ( Azuma, H; Kato, R; Kojima-Yuasa, A; Matsui-Yuasa, I, 2014) |
| "The purpose is to evaluate the CD44-mediated cellular targeting of HA-But, a hyaluronic acid esterified with butyric acid (But) residues, to hepatocellular carcinoma cell lines in vitro and to hepatic tumor metastases in vivo." | 3.72 | Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. ( Bello, M; Cantoni, S; Coradini, D; Mazzi, U; Pellizzaro, C; Perbellini, A; Rossin, R; Sava, G; Scarlata, I; Speranza, A; Turrin, C; Zorzet, S, 2004) |
| "Using in vivo and in vitro models of liver cancer, we demonstrate that an increase in the level of p53 protein in nuclei, a decrease in the level of cytoplasmic p53, and, consequently, an increase in the ratio of nuclear/cytoplasmic p53 in rat preneoplastic livers and in rat and human HCC cell lines caused by tributyrin or sodium butyrate treatments was associated with a marked increase in the level of nuclear chromosome region maintenance 1 (CRM1) protein." | 1.43 | Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein. ( Beland, FA; de Conti, A; Fernandes, LH; Furtado, KS; Heidor, R; Horst, MA; Moreno, FS; Ortega, JF; Pogribna, M; Pogribny, IP; Shpyleva, S; Tavares, PE; Tryndyak, V, 2016) |
| "Primary liver cancer has one of the highest mortality rates of all cancers, and the main current treatments have a poor prognosis." | 1.40 | Potential usefulness of baculovirus-mediated sodium-iodide symporter reporter gene as non-invasively gene therapy monitoring in liver cancer cells: an in vitro evaluation. ( Li, B; Liu, S; Pan, Y; Wu, H; Yin, H; Zhang, Y; Zhou, X, 2014) |
| "Treatment of HuH-7 human hepatocellular carcinoma (HCC) cells with 1-10 mM sodium butyrate (SB) resulted in growth inhibition in a dose-dependent manner." | 1.30 | Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. ( Fujimoto, J; Furuyama, J; Hashimoto-Tamaoki, T; Okamoto, E; Tamaoki, T; Yamamoto, H, 1998) |
| "Primary liver cancer is a significant health problem; treatment options are limited and prognosis is poor." | 1.30 | Effects of 5-azacytidine and butyrate on differentiation and apoptosis of hepatic cancer cell lines. ( Evers, BM; Li, J; Wang, X; Wang, XM, 1998) |
| "However the use of the human hepatoma cell line HepG2 as a model system for the regulation of CETP on mRNA level is facilitated by a quantitative reverse-transcribed polymerase chain reaction." | 1.29 | The expression of human plasma cholesteryl-ester-transfer protein in HepG2 cells is induced by sodium butyrate. Quantification of low mRNA levels by polymerase chain reaction. ( Budzinski, RM; Mark, M; Sperker, B, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.00) | 18.7374 |
| 1990's | 22 (55.00) | 18.2507 |
| 2000's | 2 (5.00) | 29.6817 |
| 2010's | 9 (22.50) | 24.3611 |
| 2020's | 5 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, Q | 1 |
| Dai, W | 1 |
| Ji, J | 1 |
| Wu, L | 1 |
| Feng, J | 1 |
| Li, J | 2 |
| Zheng, Y | 1 |
| Li, Y | 1 |
| Cheng, Z | 1 |
| Zhang, J | 1 |
| Wu, J | 1 |
| Xu, X | 1 |
| Guo, C | 1 |
| Kumar, M | 1 |
| Kaur, R | 1 |
| Kanthaje, S | 1 |
| Dhiman, RK | 1 |
| Chakraborti, A | 1 |
| Shou, JW | 1 |
| Shaw, PC | 1 |
| Nouso, K | 1 |
| Shiota, S | 1 |
| Fujita, R | 1 |
| Wakuta, A | 1 |
| Kariyama, K | 1 |
| Hiraoka, A | 1 |
| Atsukawa, M | 1 |
| Tani, J | 1 |
| Tada, T | 1 |
| Nakamura, S | 1 |
| Tajiri, K | 1 |
| Kaibori, M | 1 |
| Hirooka, M | 1 |
| Itobayashi, E | 1 |
| Kakizaki, S | 1 |
| Naganuma, A | 1 |
| Ishikawa, T | 1 |
| Hatanaka, T | 1 |
| Fukunishi, S | 1 |
| Tsuji, K | 1 |
| Kawata, K | 1 |
| Takaguchi, K | 1 |
| Tsutsui, A | 1 |
| Ogawa, C | 1 |
| Ochi, H | 1 |
| Yata, Y | 1 |
| Kuroda, H | 1 |
| Iijima, H | 1 |
| Matono, T | 1 |
| Shimada, N | 1 |
| Yasuda, S | 1 |
| Toyoda, H | 1 |
| Kumada, T | 1 |
| Ma, X | 1 |
| Zhou, Z | 1 |
| Zhang, X | 1 |
| Fan, M | 1 |
| Hong, Y | 1 |
| Feng, Y | 1 |
| Dong, Q | 1 |
| Diao, H | 1 |
| Wang, G | 1 |
| Quagliariello, V | 1 |
| Masarone, M | 1 |
| Armenia, E | 1 |
| Giudice, A | 1 |
| Barbarisi, M | 1 |
| Caraglia, M | 1 |
| Barbarisi, A | 1 |
| Persico, M | 1 |
| Andrade, FO | 1 |
| Furtado, KS | 2 |
| Heidor, R | 2 |
| Sandri, S | 1 |
| Hebeda, CB | 1 |
| Miranda, MLP | 1 |
| Fernandes, LHG | 1 |
| Yamamoto, RC | 1 |
| Horst, MA | 2 |
| Farsky, SHP | 1 |
| Moreno, FS | 2 |
| Hernández-Oliveras, A | 1 |
| Izquierdo-Torres, E | 1 |
| Meneses-Morales, I | 1 |
| Rodríguez, G | 1 |
| Zarain-Herzberg, Á | 1 |
| Santiago-García, J | 1 |
| Wang, HG | 1 |
| Huang, XD | 1 |
| Shen, P | 1 |
| Li, LR | 1 |
| Xue, HT | 1 |
| Ji, GZ | 1 |
| Pan, Y | 1 |
| Wu, H | 1 |
| Liu, S | 1 |
| Zhou, X | 1 |
| Yin, H | 1 |
| Li, B | 1 |
| Zhang, Y | 1 |
| Kato, R | 1 |
| Matsui-Yuasa, I | 1 |
| Azuma, H | 1 |
| Kojima-Yuasa, A | 1 |
| Ortega, JF | 1 |
| de Conti, A | 1 |
| Tryndyak, V | 1 |
| Fernandes, LH | 1 |
| Tavares, PE | 1 |
| Pogribna, M | 1 |
| Shpyleva, S | 1 |
| Beland, FA | 1 |
| Pogribny, IP | 1 |
| Kotantaki, P | 1 |
| Mosialos, G | 1 |
| Pant, K | 1 |
| Yadav, AK | 1 |
| Gupta, P | 1 |
| Islam, R | 1 |
| Saraya, A | 1 |
| Venugopal, SK | 1 |
| Coradini, D | 2 |
| Zorzet, S | 1 |
| Rossin, R | 1 |
| Scarlata, I | 1 |
| Pellizzaro, C | 1 |
| Turrin, C | 1 |
| Bello, M | 1 |
| Cantoni, S | 1 |
| Speranza, A | 2 |
| Sava, G | 1 |
| Mazzi, U | 1 |
| Perbellini, A | 1 |
| Morizane, T | 5 |
| Watanabe, T | 4 |
| Kagawa, T | 4 |
| Tsunematsu, R | 1 |
| Tada, S | 4 |
| Miyaguchi, S | 2 |
| Saito, H | 5 |
| Tsuchiya, M | 3 |
| Tsutsumi, T | 1 |
| Ido, A | 1 |
| Nakao, K | 1 |
| Hamasaki, K | 1 |
| Kato, Y | 1 |
| Ohtsuru, A | 1 |
| Nakata, K | 1 |
| Tamaoki, T | 2 |
| Nagataki, S | 1 |
| Ebinuma, H | 2 |
| Tsunematsu, S | 3 |
| Kumagai, N | 2 |
| Inagaki, Y | 1 |
| Tsuchimoto, K | 1 |
| Bode, BP | 1 |
| Souba, WW | 1 |
| Wadee, AA | 1 |
| Paterson, A | 1 |
| Coplan, KA | 1 |
| Reddy, SG | 1 |
| Sperker, B | 1 |
| Mark, M | 1 |
| Budzinski, RM | 1 |
| Velázquez, OC | 1 |
| Jabbar, A | 1 |
| DeMatteo, RP | 1 |
| Rombeau, JL | 1 |
| Atsukawa, K | 1 |
| Masuda, T | 1 |
| Ishii, H | 1 |
| Niki, S | 1 |
| Haruyama, K | 1 |
| Kokuno, S | 1 |
| Itoi, T | 1 |
| Mizoue, T | 1 |
| Takei, K | 1 |
| Mizumura, Y | 1 |
| Sanada, J | 1 |
| Mizuguchi, Y | 1 |
| Ogihara, S | 1 |
| Takeda, K | 1 |
| Onoda, K | 1 |
| Miwa, K | 1 |
| Shinohara, Y | 1 |
| Magami, Y | 1 |
| Horibe, T | 1 |
| Kakutani, H | 1 |
| Niido, T | 1 |
| Seki, T | 1 |
| Hisa, T | 1 |
| Saitou, T | 1 |
| Yamamoto, H | 1 |
| Fujimoto, J | 1 |
| Okamoto, E | 1 |
| Furuyama, J | 1 |
| Hashimoto-Tamaoki, T | 1 |
| Wang, XM | 1 |
| Wang, X | 1 |
| Evers, BM | 1 |
| Hung, WC | 1 |
| Chuang, LY | 1 |
| Watkins, SM | 1 |
| Carter, LC | 1 |
| Mak, J | 1 |
| Tsau, J | 1 |
| Yamamoto, S | 1 |
| German, JB | 1 |
| Guevara, FM | 1 |
| Kaptein, A | 1 |
| Roodenburg, L | 1 |
| Princen, HM | 1 |
| Tokiwa, T | 1 |
| Endo, A | 1 |
| Sato, J | 1 |
| Cook, JR | 1 |
| Chiu, JF | 1 |
| Tsukamoto, A | 1 |
| Kaneko, Y | 1 |
| Kurokawa, K | 1 |
| Donadel, G | 2 |
| Garzelli, C | 1 |
| Frank, R | 1 |
| Gabrielli, F | 2 |
| Li, SY | 1 |
| Bartalena, L | 1 |
| Bogazzi, F | 1 |
| Martino, E | 1 |
| Pinchera, A | 1 |
| Raymondjean, M | 1 |
| Tichonicky, L | 1 |
| Kruh, J | 1 |
| Nakagawa, T | 1 |
| Nakao, Y | 1 |
| Matsui, T | 1 |
| Koizumi, T | 1 |
| Matsuda, S | 1 |
| Maeda, S | 1 |
| Fujita, T | 1 |
1 review available for butyric acid and Liver Neoplasms
| Article | Year |
|---|---|
Histone deacetylase inhibitors for treatment of hepatocellular carcinoma.
Topics: Animals; Butyric Acid; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Enzyme Inhib | 2005 |
39 other studies available for butyric acid and Liver Neoplasms
| Article | Year |
|---|---|
Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc/hexokinase 2 pathway.
Topics: Animals; Butyric Acid; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; G | 2022 |
Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Bacteria; Butyric Acid; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Pro | 2023 |
Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma.
Topics: Animals; bcl-2-Associated X Protein; Berberine; Butyric Acid; Carcinoma, Hepatocellular; Caspase 3; | 2023 |
Effect of butyrate-producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab.
Topics: Bevacizumab; Butyric Acid; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reaction | 2023 |
Sodium butyrate modulates gut microbiota and immune response in colorectal cancer liver metastatic mice.
Topics: Animals; Butyric Acid; Cell Line, Tumor; Colorectal Neoplasms; Gastrointestinal Microbiome; Immunity | 2020 |
Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Butyric Acid; Carcinoma, Hepatocellular; Cell Survi | 2019 |
Antiangiogenic effects of the chemopreventive agent tributyrin, a butyric acid prodrug, during the promotion phase of hepatocarcinogenesis.
Topics: Actins; Angiogenesis Inhibitors; Animals; Apoptosis; Butyric Acid; Carcinogenesis; Carcinoma, Hepato | 2019 |
Histone deacetylase inhibitors promote ATP2A3 gene expression in hepatocellular carcinoma cells: p300 as a transcriptional regulator.
Topics: Animals; Butyric Acid; Carcinoma, Hepatocellular; E1A-Associated p300 Protein; Gene Expression; Hist | 2019 |
Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Butyric Acid; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tr | 2013 |
Potential usefulness of baculovirus-mediated sodium-iodide symporter reporter gene as non-invasively gene therapy monitoring in liver cancer cells: an in vitro evaluation.
Topics: Baculoviridae; Butyric Acid; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Gene Expres | 2014 |
The synergistic effect of 1'-acetoxychavicol acetate and sodium butyrate on the death of human hepatocellular carcinoma cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Benzyl Alcohols; Butyric Acid; Carc | 2014 |
Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein.
Topics: Animals; Apoptosis; Butyric Acid; Carcinoma, Hepatocellular; Cell Compartmentation; Cell Line, Tumor | 2016 |
The expression of tumor suppressor gene Cyld is upregulated by histone deacetylace inhibitors in human hepatocellular carcinoma cell lines.
Topics: Butyric Acid; Carcinoma, Hepatocellular; Cell Line, Tumor; Deubiquitinating Enzyme CYLD; Gene Expres | 2016 |
Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells.
Topics: Antineoplastic Agents; Butyric Acid; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expre | 2017 |
Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.
Topics: Animals; Butyric Acid; Carcinoma, Hepatocellular; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Surv | 2004 |
Antibody binding to liver cells and cell differentiation state.
Topics: Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Cell Differentiation; Gene Expression; Humans; I | 1995 |
Reciprocal regulation of alpha-fetoprotein and albumin gene expression by butyrate in human hepatoma cells.
Topics: Albumins; alpha-Fetoproteins; Blotting, Northern; Butyrates; Butyric Acid; Carcinoma, Hepatocellular | 1994 |
Changes of antigen expression on human hepatoma cell lines caused by sodium butyrate, a differentiation inducer.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; beta 2-Microglobulin; Butyrates; Butyric Acid; Carcinoma | 1994 |
Modulation of cellular proliferation alters glutamine transport and metabolism in human hepatoma cells.
Topics: Amino Acid Transport Systems; Amino Acids; Animals; Biological Transport; Butyrates; Butyric Acid; C | 1994 |
HLA expression in hepatocellular carcinoma cell lines.
Topics: Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Clofazimine; Enzyme-Linked Immunosorbent Assay; | 1994 |
The expression of human plasma cholesteryl-ester-transfer protein in HepG2 cells is induced by sodium butyrate. Quantification of low mRNA levels by polymerase chain reaction.
Topics: Base Sequence; Blotting, Northern; Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Carrier Prote | 1993 |
Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice.
Topics: Animals; Butyrates; Butyric Acid; Cell Division; Colorectal Neoplasms; Liver Neoplasms; Mevalonic Ac | 1996 |
Reduction of LAK-sensitivity and changes in antigen expression on hepatoma cells by sodium butyrate.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antigens, Surface; Butyrates; Butyric Acid; Car | 1996 |
[A case of hepatocellular carcinoma associated with autoimmune hepatitis and increased scintigraphy of liver accumulation].
Topics: Autoimmune Diseases; Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Female; Hepatitis; Humans; | 1997 |
Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo.
Topics: Animals; Apoptosis; Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Cell Division; Cyclin-Depend | 1998 |
Effects of 5-azacytidine and butyrate on differentiation and apoptosis of hepatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; B | 1998 |
Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-alpha.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butyric Acid; Carc | 1999 |
Butyric acid and tributyrin induce apoptosis in human hepatic tumour cells.
Topics: Acetylation; Apoptosis; Butyric Acid; Cell Nucleus; DNA Fragmentation; Histones; Humans; Liver Neopl | 1999 |
Effect of dexamethasone, dimethylsulfoxide and sodium butyrate on a human hepatoma cell line PLC/PRF/5.
Topics: alpha-Fetoproteins; Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Cell Differentiation; Cell D | 1992 |
Butyrate stimulates the secretion of apolipoprotein A-I and apolipoprotein B-100 in Hep G2 cells by different mechanisms.
Topics: Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Butyrates; Butyric Acid; Carcinoma, Hep | 1992 |
Butyrate decreases AFP and increases albumin in combination with laminin in a human hepatoma cell line.
Topics: Albumins; alpha-Fetoproteins; Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Culture Media; Hum | 1990 |
Alpha-fetoprotein mRNA: variation of half-life in rat hepatoma cell lines and destabilization by sodium butyrate.
Topics: alpha-Fetoproteins; Animals; Butyrates; Butyric Acid; Dexamethasone; Glucocorticoids; Half-Life; Liv | 1990 |
Differentiating effect of sodium butyrate on human hepatoma cell lines PLC/PRF/5, HCC-M and HCC-T.
Topics: alpha-Fetoproteins; Blotting, Northern; Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Cell Dif | 1991 |
Novobiocin modulates cytokeratin assembly and differentiation of human hepatoma cells induced by butyrate and teleocidin.
Topics: Acetylation; Butyrates; Butyric Acid; Carcinogens; Carcinoma, Hepatocellular; Cell Transformation, N | 1991 |
Identification of a novel nuclear protein synthesized in growth-arrested human hepatoblastoma HepG2 cells.
Topics: Amino Acid Sequence; Autoradiography; Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Cell Cycle | 1991 |
[Expression of cellular oncogenes in human hepatocellular carcinoma cell line BEL 7402 and the effect of sodium butyrate on the expression of cellular oncogenes].
Topics: Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Gene Expression Regulation, Neoplastic; Genes, r | 1990 |
The differentiation-inducing agent sodium butyrate produces divergent effects on albumin and thyroxine-binding globulin synthesis by human hepatoblastoma-derived (Hep G2) cells.
Topics: Albumins; Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Huma | 1990 |
Effect of sodium butyrate on the complexity and the translation activity of hepatoma tissue-cultured cell RNAs.
Topics: Animals; Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Cells, Cultured; Electrophoresis, Polya | 1985 |
Effects of sodium n-butyrate on alpha-fetoprotein and albumin secretion in the human hepatoma cell line PLC/PRF/5.
Topics: Albumins; alpha-Fetoproteins; Butyrates; Butyric Acid; Carcinoma, Hepatocellular; Cell Line; Cyclohe | 1985 |